Pain in amyotrophic lateral sclerosis: A Neglected aspect of disease

Neurology Research International

Volumn 2011, Issue , 2011, Pages

  Handy, Chalonda R ^a   Krudy, Christina ^a   Boulis, Nicholas ^a   Federici, Thais ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858337675     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2011/403808     Document Type: Review

References (87)

1. P. M. Worms, "The epidemiology of motor neuron diseases: A review of recent studies," Journal of the Neurological Sciences, vol. 191, no. 1-2, pp. 3-9, 2001. (Pubitemid 33035889)
2. J. D. Rothstein, "Current hypotheses for the underlying biology of amyotrophic lateral sclerosis," Annals of Neurology, vol. 65, no. 1, pp. S3-S9, 2009.
3. D. W. Cleveland and J. D. Rothstein, "From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS," Nature Reviews Neuroscience, vol. 2, no. 11, pp. 806-819, 2001. (Pubitemid 33674062)
4. L. P. Rowland and N. A. Shneider, "Amyotrophic lateral sclerosis," New England Journal of Medicine, vol. 344, no. 22, pp. 1688-1700, 2001. (Pubitemid 32479968)
5. L. C. Wijesekera and P. N. Leigh, "Amyotrophic lateral sclerosis," Orphanet Journal of Rare Diseases, vol. 4, no. 1, article no. 3, 2009.
6. D. Oliver, "The quality of care and symptom control-the effects on the terminal phase of ALS/MND," Journal of the Neurological Sciences, vol. 139, pp. 134-136, 1996.
7. L. Ganzini, W. S. Johnston, andW. F.Hoffman, "Correlates of suffering in amyotrophic lateral sclerosis," Neurology, vol. 52, no. 7, pp. 1434-1440, 1999. (Pubitemid 29190537)
8. P. G. Newrick and R. Langton-Hewer, "Pain in motor neuron disease," Journal of Neurology Neurosurgery and Psychiatry, vol. 48, no. 8, pp. 838-840, 1985. (Pubitemid 15005989)
9. J. Brettschneider, J. Kurent, A. Ludolph, and J. D. Mitchell, "Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease," Cochrane Database of Systematic Reviews, no. 3, Article ID CD005226, 2008.
10. J. Riley and N. M. Boulis, "Molecular mechanisms of pain: A basis for chronic pain and therapeutic approaches based on the cell and the gene," Clinical neurosurgery, vol. 53, pp. 77-97, 2006.
11. M. E. Garrity-Moses, J. K. Liu, and N.M. Boulis, "Molecular biology and gene therapy in the treatment of chronic pain," Neurosurgery Clinics of North America, vol. 14, no. 3, pp. 419-435, 2003. (Pubitemid 36876969)
12. R. Dubner andM. Gold, "The neurobiology of pain," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 7627-7630, 1999.
13. M. J. Millan, "The induction of pain: an integrative review," Progress in Neurobiology, vol. 57, no. 1, pp. 1-164, 1999. (Pubitemid 28551764)
14. C. K. Thomas and I. Zijdewind, "Fatigue ofmuscles weakened by death of motoneurons," Muscle and Nerve, vol. 33, no. 1, pp. 21-41, 2006. (Pubitemid 43062984)
15. M. Midrio, "The denervated muscle: facts and hypotheses. A historical review," European Journal of Applied Physiology, vol. 98, no. 1, pp. 1-21, 2006. (Pubitemid 44304943)
16. M. Sanjak, R. Konopacki, R. Capasso et al., "Dissociation between mechanical and myoelectrical manifestation of muscle fatigue in amyotrophic lateral sclerosis," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 5, no. 1, pp. 26-32, 2004. (Pubitemid 38618732)
17. O. Brunetti, G. Della Torre, M. L. Lucchi, R. Chiocchetti, R. Bortolami, and V. E. Pettorossi, "Inhibition of muscle spindle afferent activity during masseter muscle fatigue in the rat," Experimental Brain Research, vol. 152, no. 2, pp. 251-262, 2003. (Pubitemid 37153646)
18. M. M. Panjabi, "A hypothesis of chronic back pain: ligament subfailure injuries lead to muscle control dysfunction," European Spine Journal, vol. 15, no. 5, pp. 668-676, 2006.
19. H. Degens and S. E. Alway, "Control of muscle size during disuse, disease, and aging," International Journal of Sports Medicine, vol. 27, no. 2, pp. 94-99, 2006. (Pubitemid 43288519)
20. T. S. Gross, S. L. Poliachik, J. Prasad, and S. D. Bain, "The effect of muscle dysfunction on bone mass and morphology," Journal of Musculoskeletal Neuronal Interactions, vol. 10, no. 1, pp. 25-34, 2010.
21. Y. X. Qin, H. Lam, S. Ferreri, and C. Rubin, "Dynamic skeletal muscle stimulation and its potential in bone adaptation," Journal of Musculoskeletal Neuronal Interactions, vol. 10, no. 1, pp. 12-24, 2010.
22. R. R. Young, "Spasticity: A review," Neurology, vol. 44, no. 11, pp. S12-S20, 1994.
23. G. Sheean, "The pathophysiology of spasticity," European Journal of Neurology, vol. 9, supplement 1, pp. 3-9, 2002. (Pubitemid 41759594)
24. J. Singerman and L. Lee, "Consistency of the Babinski reflex and its variants," European Journal of Neurology, vol. 15, no. 9, pp. 960-964, 2008.
25. G. D. Borasio and R. Voltz, "Palliative care in amyotrophic lateral sclerosis," Journal of Neurology, vol. 244, no. 4, pp. S11-S17, 1997.
26. G. D. Borasio, "Palliative care in ALS: searching for the evidence base," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 2, no. 1, pp. S31-S35, 2001.
27. G. D. Borasio and R. G. Miller, "Clinical characteristics and management of ALS," Seminars in Neurology, vol. 21, no. 2, pp. 155-166, 2001. (Pubitemid 32578727)
28. G. T. Carter and R. G. Miller, "Comprehensive management of amyotrophic lateral sclerosis," Physical Medicine and Rehabilitation Clinics of North America, vol. 9, no. 1, pp. 271-284, 1998. (Pubitemid 28134031)
29. K. Blatzheim, "Interdisciplinary palliative care, including massage, in treatment of amyotrophic lateral sclerosis," Journal of Bodywork and Movement Therapies, vol. 13, no. 4, pp. 328-335, 2009.
30. S. Khodadadeh and S.M. Eisenstein, "Gait analysis of patients with low back pain before and after surgery," Spine, vol. 18, no. 11, pp. 1451-1455, 1993. (Pubitemid 23270908)
31. K. M. Kelly, W. Doyle, and H. B. Skinner, "The relationship between gait parameters and pain in persons with transtibial amputation: A preliminary report," Journal of Rehabilitation Research and Development, vol. 35, no. 2, pp. 231-237, 1998. (Pubitemid 28303950)
32. M. A. Kroll, J. C. Otis, T. P. Sculco et al., "The relationship of stride characteristics to pain before and after total knee arthroplasty," Clinical Orthopaedics and Related Research, no. 239, pp. 191-195, 1989. (Pubitemid 19060610)
33. J. M. Hausdorff, A. Lertratanakul, M. E. Cudkowicz, A. L. Peterson, D. Kaliton, and A. L. Goldberger, "Dynamicmarkers of altered gait rhythmin amyotrophic lateral sclerosis," Journal of Applied Physiology, vol. 88, no. 6, pp. 2045-2053, 2000. (Pubitemid 30453909)
34. K. R. Sharma and R. G. Miller, "Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis," Muscle and Nerve, vol. 19, no. 11, pp. 1391-1400, 1996. (Pubitemid 26349495)
35. J. Mitchell and G. Borasio, "Amyotrophic lateral sclerosis," Lancet, vol. 369, no. 9578, pp. 2031-2041, 2007. (Pubitemid 46899183)
36. A. S. Mayadev, M. D. Weiss, B. Jane Distad, L. S. Krivickas, and G. T. Carter, "The amyotrophic lateral sclerosis center: A model of multidisciplinary management," Physical Medicine and Rehabilitation Clinics of North America, vol. 19, no. 3, pp. 619-631, 2008. (Pubitemid 351952455)
37. S.McClelland, F. A. Bethoux, N. M. Boulis et al., "Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief," Muscle and Nerve, vol. 37, no. 3, pp. 396-398, 2008. (Pubitemid 351304800)
38. S. McClelland III, Q. Teng, L. S. Benson, and N. M. Boulis, "Motor neuron inhibition-based gene therapy for spasticity," American Journal of Physical Medicine and Rehabilitation, vol. 86, no. 5, pp. 412-421, 2007. (Pubitemid 46652199)
39. P. Corcia and V. Meininger, "Management of amyotrophic lateral sclerosis," Drugs, vol. 68, no. 8, pp. 1037-1048, 2008. (Pubitemid 351693674)
40. P. N. Leigh, S. Abrahams, A. Al-Chalabi et al., "The management of motor neurone disease," Neurology in Practice, vol. 74, no. 4, pp. iv32-iv47, 2003.
41. T. O'Brien, M. Kelly, and C. Saunders, "Motor neurone disease: A hospice perspective," British Medical Journal, vol. 304, no. 6825, pp. 471-473, 1992.
42. Z. Simmons, "Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death," Neurologist, vol. 11, no. 5, pp. 257-270, 2005. (Pubitemid 41327385)
43. D. A. Restivo, S. Lanza, R. Marchese-Ragona, and A. Palmeri, "Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis," Gastroenterology, vol. 123, no. 5, pp. 1749-1750, 2002. (Pubitemid 35231676)
44. M. G. M. Winterholler, J. G. Heckmann, M. Hecht, and F. J. Erbguth, "Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin," Neurology, vol. 58, no. 3, pp. 502-503, 2002. (Pubitemid 34150941)
45. T. Mezaki, R. Kaji, N. Kohara, and J. Kimura, "Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection," Neurology, vol. 46, no. 3, pp. 845-846, 1996. (Pubitemid 26099666)
46. B. R. Snyder, N. M. Boulis, and T. Federici, "Viral vectormediated gene transfer for CNS disease," Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 381-394, 2010.
47. T. Federici andN. M. Boulis, "Gene-based treatment ofmotor neuron diseases,"Muscle and Nerve, vol. 33, no. 3, pp. 302-323, 2006.
48. D. Wolfe, M. Mata, and D. J. Fink, "A human trial of HSVmediated gene transfer for the treatment of chronic pain," Gene Therapy, vol. 16, no. 4, pp. 455-460, 2009.
49. D. Wolfe, J. Wechuck, D. Krisky, M. Mata, and D. J. Fink, "A clinical trial of gene therapy for chronic pain," Pain Medicine, vol. 10, no. 7, pp. 1325-1330, 2009.
50. K. K. Jain, "Gene therapy for pain," Expert Opinion on Biological Therapy, vol. 8, no. 12, pp. 1855-1866, 2008.
51. M. Mata, S. Hao, and D. J. Fink, "Applications of gene therapy to the treatment of chronic pain," Current Gene Therapy, vol. 8, no. 1, pp. 42-48, 2008. (Pubitemid 351485839)
52. D. K. Cope and W. R. Lariviere, "Gene therapy and chronic pain," TheScientificWorldJournal, vol. 6, pp. 1066-1074, 2006. (Pubitemid 44440818)
53. J. C. Glorioso, M. Mata, and D. J. Fink, "Gene therapy for chronic pain," Current Opinion in Molecular Therapeutics, vol. 5, no. 5, pp. 483-488, 2003. (Pubitemid 37304713)
54. J. Kim, Y. S. Yoon, H. Lee, and J. W. Chang, "AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease," Acta neurochirurgica. Supplement, vol. 101, pp. 99-105, 2008.
55. J. P. Vit, P. T. Ohara, C. Sundberg et al., "Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia," Molecular Pain, vol. 5, article no. 42, 2009.
56. S.Hao,M.Mata,D.Wolfe, J.C.Glorioso, andD. J. Fink, "Gene transfer of glutamic acid decarboxylase reduces neuropathic pain," Annals of Neurology, vol. 57, no. 6, pp. 914-918, 2005. (Pubitemid 40798630)
57. K. Asanuma, C. Tang, Y. Ma et al., "Network modulation in the treatment of Parkinson's disease," Brain, vol. 129, no. 10, pp. 2667-2678, 2006. (Pubitemid 44522100)
58. A. Feigin, M. G. Kaplitt, C. Tang et al., "Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19559-19564, 2007.
59. M. G. Kaplitt, A. Feigin, C. Tang et al., "Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial," Lancet, vol. 369, no. 9579, pp. 2097-2105, 2007. (Pubitemid 46935946)
60. Q. Teng, D. K. Tanase, J. K. Liu, M. E. Garrity-Moses, K. B. Baker, and N. M. Boulis, "Adenoviral clostridial light chain gene-based synaptic inhibition through neuronal synaptobrevin elimination," Gene Therapy, vol. 12, no. 2, pp. 108-119, 2005. (Pubitemid 40185914)
61. Z. Zhao, A. Krishnaney, Q. Teng et al., "Anatomically discrete functional effects of adenoviral clostridial light chain genebased synaptic inhibition in the midbrain," Gene Therapy, vol. 13, no. 12, pp. 942-952, 2006. (Pubitemid 43827336)
62. V. Neugebauer, T. Lucke, and H. G. Schaible, "Differential effects of N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists on the responses of rat spinal neurons with joint input," Neuroscience Letters, vol. 155, no. 1, pp. 29-32, 1993. (Pubitemid 23186662)
63. V. Neugebauer, T. Lucke, and H. G. Schaible, "N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint," Journal of Neurophysiology, vol. 70, no. 4, pp. 1365-1377, 1993. (Pubitemid 23326374)
64. K. A. Sluka, "Pain mechanisms involved in musculoskeletal disorders," Journal of Orthopaedic and Sports Physical Therapy, vol. 24, no. 4, pp. 240-254, 1996. (Pubitemid 126752380)
65. H. G. Schaible, "Spinal mechanisms contributing to joint pain," Novartis Foundation Symposium, vol. 260, pp. 4-27, 2004.
66. H.G. Schaible, A. Ebersberger, andG. S.Von Banchet, "Mechanisms of pain in arthritis," Annals of the New York Academy of Sciences, vol. 966, pp. 343-354, 2002. (Pubitemid 34729193)
67. H. G. Schaible, F. Richter, A. Ebersberger et al., "Joint pain," Experimental Brain Research, vol. 196, no. 1, pp. 153-162, 2009.
68. K. A. Sluka and K. N. Westlund, "An experimental arthritis model in rats: The effects of NMDA and non-NMDA antagonists on aspartate and glutamate release in the dorsal horn," Neuroscience Letters, vol. 149, no. 1, pp. 99-102, 1993. (Pubitemid 23022140)
69. S. M. South, T. Kohno, B. K. Kaspar et al., "A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injuryinduced pain," Journal of Neuroscience, vol. 23, no. 12, pp. 5031-5040, 2003. (Pubitemid 36793230)
70. R. Przewlocki and B. Przewlocka, "Opioids in chronic pain," European Journal of Pharmacology, vol. 429, no. 1-3, pp. 79-91, 2001. (Pubitemid 33043984)
71. S. Hao, M. Mata, W. Goins, J. C. Glorioso, and D. J. Fink, "Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain," Pain, vol. 102, no. 1-2, pp. 135-142, 2003. (Pubitemid 36298869)
72. J. R. Goss, M. Mata,W. F. Goins, H. H. Wu, J. C. Glorioso, and D. J. Fink, "Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion," Gene Therapy, vol. 8, no. 7, pp. 551-556, 2001. (Pubitemid 32409530)
73. D.C.Yeomans,Y. Lu, C. E. Laurito et al., "Recombinantherpes vector-mediated analgesia in a primate model of hyperalgesia," Molecular Therapy, vol. 13, no. 3, pp. 589-597, 2006. (Pubitemid 43257627)
74. W. Kang, M. A. Wilson, M. A. Bender, J. C. Glorioso, and S. P. Wilson, "Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive," Brain Research, vol. 792, no. 1, pp. 133-135, 1998. (Pubitemid 28261177)
75. U. Baron and H. Bujard, "Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances," Methods in Enzymology, vol. 327, pp. 401-421, 2000. (Pubitemid 34193323)
76. U. C. Hoppe, E. Marbán, and D. C. Johns, "Adenovirusmediated inducible gene expression in vivo by a hybrid ecdysone receptor," Molecular Therapy, vol. 1, no. 2, pp. 159-164, 2000.
77. X. Ye, V. M. Rivera, P. Zoltick et al., "Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer," Science, vol. 283, no. 5398, pp. 88-91, 1999. (Pubitemid 29045765)
78. Y. Wang, B. W. O'Malley, S. Y. Tsai, and B. W. O'Malley, "A regulatory system for use in gene transfer," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 17, pp. 8180-8184, 1994. (Pubitemid 24253910)
79. H. Andersson and K. Alestig, "The penetration of doxycycline into CSF," Scandinavian Journal of Infectious Diseases, Supplement, no. 9, pp. 17-19, 1976. (Pubitemid 8003894)
80. M. Barza, R. B. Brown, and C. Shanks, "Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs," Antimicrobial Agents and Chemotherapy, vol. 8, no. 6, pp. 713-720, 1975.
81. B. K. Kaspar, J. Lladó, N. Sherkat, J. D. Rothstein, and F. H. Gage, "Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model," Science, vol. 301, no. 5634, pp. 839-842, 2003. (Pubitemid 36962626)
82. S.W. Tolle, V. P. Tilden, A. G. Rosenfeld, and S. E. Hickman, "Family reports of barriers to optimal care of the dying," Nursing Research, vol. 49, no. 6, pp. 310-317, 2000.
83. S. W. Tolle, V. P. Tilden, S. E. Hickman, and A. G. Rosenfeld, "Family reports of pain in dying hospitalized patients: A structured telephone survey," Western Journal of Medicine, vol. 172, no. 6, pp. 374-377, 2000. (Pubitemid 30390514)
84. S. E. Hickman, S. W. Tolle, and V. P. Tilden, "Physicians' and nurses' perspectives on increased family reports of pain in dying hospitalized patients," Journal of Palliative Medicine, vol. 3, no. 4, pp. 413-418, 2000. (Pubitemid 32056753)
85. D. A. Monti and E. J. S. Kunkel, "Practical geriatrics: management of chronic pain among elderly patients," Psychiatric Services, vol. 49, no. 12, pp. 1537-1539, 1998. (Pubitemid 28563645)
86. C. S. Cleenland, "Undertreatment of cancer pain in elderly patients," Journal of the American Medical Association, vol. 279, no. 23, pp. 1914-1915, 1998. (Pubitemid 28299290)
87. S. E.Ward, N. Goldberg, V.Miller-McCauley et al., "Patientrelated barriers to management of cancer pain," Pain, vol. 52, no. 3, pp. 319-324, 1993. (Pubitemid 23080550)